This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Experimental Treatment in a Rabbit Model

Robert W. Snyder, MD, PhD; Fred H. Lambrou, MD; George A. Williams, MD

Arch Ophthalmol. 1987;105(9):1277-1280.

Abstract
• Intraocular fibrin formation following ocular surgery is a potentially blinding problem. Current therapy for this postoperative fibrin response is often ineffective. In the rabbit, we developed a quantitative reproducible model for intraocular fibrin deposition. Using this model, wehave tested the efficacy of human tissue plasminogen activator (tPA) in promoting intraocular fibrinolysis. Citrated rabbit plasma (0.2 mL) was injected intracamerally following paracentesis, resulting in fibrin clot formation within three hours. The fibrin clots were stable for four days, and then slowly lysed over the next four days. Approximately 24 hours after clot formation, various concentrations of human tPA were injected intracamerally. The time taken for clot lysis was dose dependent, with 1800 IU of tPA producing clot lysis in three hours. Toxicity, as measured by intraocular pressure, corneal thickness, inflammation, or cataract formation, was minimal.

Author Affiliations
From the Department of Ophthalmology, Medical College of Wisconsin, Milwaukee.

Footnotes
Accepted for publication May 29, 1987.

Reprint requests to Eye Institute, Medical College of Wisconsin, 8700 W Wisconsin Ave, Milwaukee, WI 53226 (Dr Williams).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery
Siatiri et al.
Br J Ophthalmol 2005;89:1458-1461.
ABSTRACT | FULL TEXT  

Recombinant tissue plasminogen activator following paediatric cataract surgery
Mehta and Adams
Br J Ophthalmol 2000;84:983-986.
ABSTRACT | FULL TEXT  

Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study
Heiligenhaus et al.
Br J Ophthalmol 1998;82:810-815.
ABSTRACT | FULL TEXT  

Tissue Plasminogen Activator and Staphylococcus epidermidis Endophthalmitis
Ryan and Mizener
Arch Ophthalmol 1993;111:1117-1122.
ABSTRACT  

Intraocular Penetration of Topical Tissue Plasminogen Activator
Lim et al.
Arch Ophthalmol 1991;109:714-717.
ABSTRACT  

Retinal Toxicity of Human Tissue Plasminogen Activator in Vitrectomized Rabbit Eyes
Irvine et al.
Arch Ophthalmol 1991;109:718-722.
ABSTRACT  

Intraocular Tissue Plasminogen Activator in a Rabbit Model of Traumatic Hyphema
Howard et al.
Arch Ophthalmol 1991;109:272-274.
ABSTRACT  

The Effect of Tissue Plasminogen Activator on Retinal Bleeding
Sternberg et al.
Arch Ophthalmol 1990;108:720-722.
ABSTRACT  

Retinal Toxicity of Recombinant Tissue Plasminogen Activator in the Rabbit
Johnson et al.
Arch Ophthalmol 1990;108:259-263.
ABSTRACT  

Rebleeding in Experimental Traumatic Hyphema Treated With Intraocular Tissue Plasminogen Activator
Williams et al.
Arch Ophthalmol 1990;108:264-266.
ABSTRACT  

Intravitreal Tissue Plasminogen Activator Treatment of Experimental Vitreous Hemorrhage
Johnson et al.
Arch Ophthalmol 1989;107:891-894.
ABSTRACT  

Treatment of Postvitrectomy Fibrin Formation With Intraocular Tissue Plasminogen Activator
Williams et al.
Arch Ophthalmol 1988;106:1055-1058.
ABSTRACT